Paramount Global (PARA)

[surf1944]

AP
ViaCell Expanding ViaCord Facility
Tuesday September 18, 8:08 am ET
ViaCell, Expecting Future Demand, Doubling Storage Capacity in Its ViaCord Operation

CAMBRIDGE, Mass. (AP) -- Biotechnology company ViaCell Inc. said Tuesday it expects to complete expansion of its ViaCord processing facility in the first quarter.

The company did not disclose the estimated cost of the expansion or provide details on how it is enlarging the facility, except to say it would double current storage capacity. ViaCell officials could not immediately be reached for comment.

The expansion comes as the company expects demand for its ViaCord product to increase, it said in a statement. The company said ViaCord preserves umbilical cord blood for medical use, including stem-cell applications for cancer treatment.

ViaCell said its has preserved the umbilical cord blood of over 130,000 newborns.

also

ViaCell to Present at the 2007 UBS Global Life Sciences Conference

ViaCell, Inc. (NASDAQ: VIAC) today announced that Marc D. Beer, President and Chief Executive Officer of ViaCell, will present an update on its business activities and product pipeline at the 2007 UBS Global Life Sciences Conference on Monday, September 24, 2007 at 12:00 p.m. at the Grand Hyatt Hotel in New York, NY. A live audio webcast of the presentation will be available on the Investor Information section of the ViaCell website at http://www.viacellinc.com. A replay of the presentation will be available for approximately three months after the webcast.

About ViaCell

ViaCell, Inc. is a biotechnology company dedicated to enabling the widespread application of human cells as medicine. The Company markets ViaCord®, a product offering through which families can preserve their baby’s umbilical cord blood at the time of birth for possible future medical use in treating over 40 diseases including certain blood cancers and genetic diseases. The Company is also working to leverage its commercial infrastructure and product development capabilities by developing ViaCyteSM, a product candidate being studied for its potential to broaden reproductive choices for women through the cryopreservation of human unfertilized eggs. ViaCell also conducts research and development primarily to investigate other potential therapeutic uses of umbilical cord blood-derived stem cells and on technology for expanding populations of these cells. ViaCell’s pipeline is focused in the areas of cancer, cardiac disease, and diabetes. For more information about ViaCell, visit our website at http://www.viacellinc.com.

ViaCell® and ViaCord® are registered trademarks and ViaCyteSM is a service mark of ViaCell, Inc.

ViaCell, Inc.
Justine E. Koenigsberg, 617-914-3494
Senior Director, Corporate Communications


Source: Business Wire (September 18, 2007 - 6:31 AM EST)

News by QuoteMedia
www.quotemedia.com